Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach. For further information, please visit www.angion.com.

Angion recognizes the importance of offering our employees a comprehensive total rewards framework.  We offer the following benefits:

• Competitive Salary, Bonus and Equity Programs (Stock Options)
• Comprehensive medical (HMO,PPO, EPO), dental and vision plans
• SIMPLE IRA Plan with company match
• 3 Weeks Vacation Time
• 14 Paid Holidays (including a year-end shut down)
• Life and AD&D Coverage
• Short and Long Term Disability
• Voluntary Benefits
• Flexible Spending Accounts